Abstract
Tumor cell proliferation, de-differentiation, and progression depend on a complex combination of altered intracellular processes including cell cycle regulation, excessive growth factor pathway activation, and decreased apoptosis. Metabolites from these processes result in significant cellular oxidative stress that must be buffered to prevent permanent cell damage and cell death. Tumor cells depend on a complex set of respiratory pathways to generate the necessary energy as well as redox-sensitive pro-survival signaling pathways and factors to cope with and defend against the detrimental effects of oxidative stress. It has been hypothesized that redox-sensitive signaling factors such as thioredoxin reductase-1 (TR) and thioredoxin (TRX) may represent central pro-survival factors that would allow tumor cells to evade the damaging and potentially cytotoxic effects of endogenous and exogenous agents that induce oxidative stress. The overarching theme of this review is an extension of the hypothesis that tumor cells use these redox sensitive pro-survival signaling pathways/factors, which are up-regulated due to increased tumor cell respiration, to evade the cytotoxic effects of anticancer agents. These observations suggest that redox-sensitive signaling factors may be potential novel molecular targets for drug discovery.
Keywords: Molecular targets, redox signaling, anticancer drug resistance, thioredoxin
Current Pharmaceutical Design
Title: Thioredoxin and Thioredoxin Reductase As Redox-Sensitive Molecular Targets for Cancer Therapy
Volume: 13 Issue: 33
Author(s): J. Daniel Pennington, Kristi Muldoon Jacobs, Lunching Sun, Gil Bar-Sela, Mark Mishra and David Gius
Affiliation:
Keywords: Molecular targets, redox signaling, anticancer drug resistance, thioredoxin
Abstract: Tumor cell proliferation, de-differentiation, and progression depend on a complex combination of altered intracellular processes including cell cycle regulation, excessive growth factor pathway activation, and decreased apoptosis. Metabolites from these processes result in significant cellular oxidative stress that must be buffered to prevent permanent cell damage and cell death. Tumor cells depend on a complex set of respiratory pathways to generate the necessary energy as well as redox-sensitive pro-survival signaling pathways and factors to cope with and defend against the detrimental effects of oxidative stress. It has been hypothesized that redox-sensitive signaling factors such as thioredoxin reductase-1 (TR) and thioredoxin (TRX) may represent central pro-survival factors that would allow tumor cells to evade the damaging and potentially cytotoxic effects of endogenous and exogenous agents that induce oxidative stress. The overarching theme of this review is an extension of the hypothesis that tumor cells use these redox sensitive pro-survival signaling pathways/factors, which are up-regulated due to increased tumor cell respiration, to evade the cytotoxic effects of anticancer agents. These observations suggest that redox-sensitive signaling factors may be potential novel molecular targets for drug discovery.
Export Options
About this article
Cite this article as:
Pennington Daniel J., Jacobs Muldoon Kristi, Sun Lunching, Bar-Sela Gil, Mishra Mark and Gius David, Thioredoxin and Thioredoxin Reductase As Redox-Sensitive Molecular Targets for Cancer Therapy, Current Pharmaceutical Design 2007; 13 (33) . https://dx.doi.org/10.2174/138161207782360537
DOI https://dx.doi.org/10.2174/138161207782360537 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interactions of Metal Ions with DNA, Its Constituents and Derivatives, which may be Relevant for Anticancer Research
Current Topics in Medicinal Chemistry Hecogenin Acetate Inhibits Reactive Oxygen Species Production and Induces Cell Cycle Arrest and Senescence in the A549 Human Lung Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Lipid Rafts, Endoplasmic Reticulum and Mitochondria in the Antitumor Action of the Alkylphospholipid Analog Edelfosine
Anti-Cancer Agents in Medicinal Chemistry The Coronin Family and Human Disease
Current Protein & Peptide Science Role of Polyamines in Breast Cancer Growth, Development and Progression
Current Cancer Therapy Reviews Potential Application of Induced Pluripotent Stem Cells in Cell Replacement Therapy for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Insight to Physiology and Pathology of Zinc(II) Ions and Their Actions in Breast and Prostate Carcinoma
Current Medicinal Chemistry Editorial (Thematic Issue: Metabolic Disorders, Drug Development, Drug Design and Biomarkers)
Current Pharmaceutical Design Mechanism-Based Treatment in Chronic Neuropathic Pain: The Role of Antidepressants
Current Pharmaceutical Design Activation of the dsRNA-Activated Protein Kinase PKR in Mitochondrial Dysfunction and Inflammatory Stress in Metabolic Syndrome
Current Pharmaceutical Design Bypassing Cancer Resistance by Antagonizing “Inhibitor of Apoptosis Proteins” (IAPs)
Current Signal Transduction Therapy Novel HSP90 Inhibitor NVP-AUY922 Enhances the Anti-tumor Effect of Temsirolimus Against Oral Squamous Cell Carcinoma
Current Cancer Drug Targets Purine Ionotropic (P2X) Receptors
Current Pharmaceutical Design Cyclodextrin-based Polymeric Nanoparticles as Efficient Carriers for Anticancer Drugs
Current Pharmaceutical Biotechnology Identification of Potential Targets for Thymidylate Synthase and Amp-C β-lactamase from Non-alkaloidal Fractions of <i>Moringa oleifera</i> Leaves
Current Pharmaceutical Biotechnology A Curcumin Analog, GO-Y078, Effectively Inhibits Angiogenesis through Actin Disorganization
Anti-Cancer Agents in Medicinal Chemistry Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers
Recent Patents on Anti-Cancer Drug Discovery Next Generation Tyrosine Kinase Inhibitor (TKI): Afatinib
Recent Patents on Anti-Cancer Drug Discovery TGR5 as a Therapeutic Target for Treating Obesity
Current Topics in Medicinal Chemistry Designing and In-Vitro Characterization of Micelle Forming Amphiphilic PEGylated Rapamycin Nanocarriers for the Treatment of Gastric Cancer
Current Drug Delivery